Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome

Current Pharmaceutical Design

Volumn 10, Issue 28, 2004, Pages 3561-3568

  Evangelista, S ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

Calcium channels; Cimetropium bromide; Irritable bowel syndrome (IBS); Muscarinic receptors; n butyl scopolammonium bromide (Buscopan); Otilonium bromide; Pinaverium bromide; Spasmolytic

Indexed keywords

ALOSETRON; ATROPINE; CALCIUM CHANNEL L TYPE; CIMETROPIUM; MEBEVERINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OTILONIUM BROMIDE; PAPAVERINE; PINAVERIUM BROMIDE; QUATERNARY AMMONIUM DERIVATIVE; SCOPOLAMINE BUTYL BROMIDE; SPASMOLYTIC AGENT; TEGASEROD; TRIMEBUTINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE DISEASE; ANTICHOLINERGIC EFFECT; BLADDER DISEASE; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CHRONIC DISEASE; CLINICAL TRIAL; COLIC; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; FECES ANALYSIS; GASTROINTESTINAL TRACT; HEPATOBILIARY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; META ANALYSIS; METHODOLOGY; MOLECULAR DYNAMICS; MYDRIASIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CONDUCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; VALIDATION PROCESS; XEROSTOMIA;

BUTYLSCOPOLAMMONIUM BROMIDE; CLINICAL TRIALS; HUMANS; IRRITABLE BOWEL SYNDROME; MORPHOLINES; PARASYMPATHOLYTICS; QUATERNARY AMMONIUM COMPOUNDS; SCOPOLAMINE DERIVATIVES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5744241657     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382972     Document Type: Review

References (62)

1. Ghelardoni M, Pestellini V, Pisanti N, Volterra G. Quaternary salts of substituted 2-aminoethyl N-Benzoylaminobenzoate. A new class of smooth muscle relaxant agents. J Med Chem 1973; 16: 1063-5.
2. Baronnet R, Foussard-Blanpin O, Bretaudeau J, Hubert F. Synthèse et ètude pharmacodynamique comparée d'ammoniums quaternaires dérivés du diméthyl-6, 6 norpinane: leur action spasmolytique. Eur J Med Chem 1974; 2:182-7.
3. Schiavone A, Schiavi GB, De Conti L, Micheletti R, Sagrada A, Hammer R, et al. Cimetropium: characterization of antimuscarinic and spasmolytic properties. Arzneim Forsch/Drug Res 1985; 35: 796-9.
4. Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. Receptor binding profile of otilonium bromide. Pharmacol Res 1998; 38: 111-7.
5. Maggi CA, Manzini S, Meli A. Octylonium Bromide: a smooth muscle relaxant which interferes with calcium ions mobilisation. Arch Int Pharmacodyn Therap 1983; 264:305-23.
6. Maggi CA, Meli A. Assessment of potential selectivity of antispasmodics for the various sections of the gastrointestinal tract of the rat as a guideline for their clinical use. Arch Int Pharmacodyn Therap 1983; 262:221-30.
7. Christen M.O. Action of Pinaverium Bromide, a calcium-antagonist, on gastrointestinal motility disorders. Gen Pharmac 1990; 21: 821-5.
8. Scarpignato C, Bianchi Porro G. Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic persectives. Int J Clin Pharm Res 1985, 5: 467-77.
9. Evangelista S. Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res 1999; 27:207-22.
10. Maggi CA, Meli A. Eserine-induced hypertone of guinea pig distal colon in vivo: a new pharmacological procedure for testing smooth muscle relaxants. J Pharmacol Methods 1984; 12:91-6.
11. Eglen RM, Hedge SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996, 48:531-65.
12. Manzini S, Maggi CA, Meli A. System and organ selectivity of smooth muscle relaxants on in vitro spontaneously contracting preparations. Arch Int Pharmacodyn Ther 1984; 270:50-60.
13. Feron O, Wibo M, Christen MO, Godfraind T. Interaction of pinaverium (a quaternary ammonium compound) with 1, 4-dihydropyridine binding sites in rat ileum smooth muscle. Br J Pharmacol 1992; 105:480-4.
14. McFadzean I, Gibson A. The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol 2002; 135: 1-13.
15. Yoshino M, Someva T, Nishino A, Yabu H. Whole-cell and unitary Ca channel currents in mammalian intestinal smooth muscle cells: evidence for the existence of two types of Ca channels. Pfugers Arch 1988; 411: 229-31.
16. Ahmad S, Rausa J Jamg E, Daniel EE. Calcium channels binding in nerves and muscle of canine small intestine. Biochem Biophys Res Comm 1988; 411: 119-25.
17. 2+ channels and secretion in rat chromaffin cells. Eur J Pharmacol 1996; 298:199-205.
18. Morel N, Buryi V, Feron O, Gomez J, Christen M, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel α1-subunits. Br J Pharmacol 1998; 125: 1005-12.
19. Boyer JC, Magous R, Christen MO, Balmes JL, Bali JP. Contraction of human circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. Cell Calcium 2001; 29: 429-38.
20. Strege PR, Evangelista S, Lyford GL, Sarr MG, Farrugia G. Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastrenterol Motil 2004; 16: 167-73.
21. Evangelista S. Involvement of tachykinins in intestinal inflammation. Curr Pharm Des 2001; 7: 19-30.
22. 2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon. Naunyn-Schmied. Arch Pharmacol 1999; 359: 420-7.
23. Evangelista S, Patacchini R, Maggi CA. Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems. Curr Med Chem-Anti-Inflammatory & Anti-Allergy Agents 2003; 2: 157-74.
24. Holzer P, Michl T, Danzer M, Jocic M, Schicho R, Lippe Ith. Surveillance of the gastrointestinal mucosa by sensory neurons. J Physiol Pharmacol 2001; 4: 505-21.
25. Jacquot C, Trouvin JH, Christen MO. In: Christen MO, Godfraind T, McCallum RW. Ed, Calcium antagonism in gastrointestinal motility. Paris, Elsevier, 1989; 141-51.
26. Amenta F, Baroldi P, Ferrante F, Napoleone P, Meli A. Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract. Arch int Pharmacodyn Ther 1991; 311:5-19.
27. Waldek F. The intestinal absorption of scopolamine-N-butyl bromide (Buscopan ®) from isolated loops in conscious rats. Eur J Pharmacol 1969; 8: 108-12.
28. 14C pinaverium bromide synthesis and pharmacokinetics study in the rat. Eur J Med Chem 1978; 13: 61-6.
29. Borchers F, Achtert G. Metabolism of pinaverium bromide (Dicetel ®) in rat, dog and man. Elucidation of the structures of the major metabolites by combined electron impact and field resorption mass spectrometry. Analyt Chem Symp Series 1981; 7: 39-56.
30. 14C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Disp 2000; 28: 643-7.
31. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
32. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
33. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17: 331-8.
34. Jailwala J, Imperiale TF, Kroenke K. Pharmacological treatment of irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Int Med 2000; 133: 136-47.
35. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15:355-61.
36. Poynard T, Regimbeau C, Benhamou Y. Review: smooth muscle relaxants improve symptoms and reduce pain in irritable bowel syndrome. Am Coll Physic Journal 2001; 135: 53-5.
37. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double-blind placebo controlled clinical trial. Gut 1990; 31:355-8.
38. Centonze V, Imbimbo BP, Camponazzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83:1262-6.
39. Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam 1995; 25:137-44.
40. Piai G, Mazzacca G. Prifinium bromide in the treatment of irritable bowel syndrome. Gastroenterology 1979; 77:500-2.
41. Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, et al. Octylonium bromide in the treatment of the irritable bowel syndrome: A clinical-function study. Hepato-Gastroenterol 1992; 39:392-5.
42. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, et al. Otilonium bromide in irritable bowel syndrome: a multicenter double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998; 12:1003-10.
43. Piai G, Visconti M, Imbimbo BP, Minieri M, Sollazzo R, Mazzacca G. Long term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound. Curr Ther Res 1987; 21: 967-77.
44. Passaretti S, Guslandi M, Imbimbo BO, Daniotti S, Tittobello A. Effects to cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1989; 3: 267-76.
45. Richtie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butyl bromide, and ispagula husk. Br Med J 1979; 1: 376-8.
46. Nigam P, Kappor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regiments in irritable bowel syndrome. J Assoc Phys India 1984; 32: 1041-4.
47. Shafer VE, Ewe K. Behandlung des colon irritabile. Fortschr Med 1990; 25: 488-92.
48. Barbier P. Etude controllèe en double aveugle d'un nouvel antispasmodique colique. Ars Med 1981; 21: 1879-80.
49. Baldi F, Corinaldesi R, Ferrarini F, Balestra R, Brunetti G, Cassan L et al. Clinical and functional evaluation of octylonium bromide in the treatment of irritable bowel syndrome. Clinical Trials J 1983; 20: 77-88.
50. Castiglione F, Daniele B, Mazzacca G. Therapeutic strategy for the irritable bowel syndrome. Ital J Gastroenterol 1991; 23 (Suppl 1): 53-5.
51. Levy C, Charbonnier A, Cachin M. Bromure de pinaverium et colopathie fonctionelle. Sem Hop Paris Ther 1977; 53: 7-8.
52. Delmont J. Intérêt de l'adjonction d'un antispasmodique musculotrope an traitement des costipations douloureuses des colopathies fonctionnelles par le son. Med Chir Dig 1981; 4: 365-70.
53. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind placebo-controlled 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002; 14:1331-8.
54. Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, Dukes GE, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J intern Med Res 1998: 26: 76-81.
55. Veldhuysen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl II): 1169-77.
56. Bardhan KD, Bodemar G, Geldof H, Schutz E, Heath A, Mills JG, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
57. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
58. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
59. Novick J, Miner P, Krause R, Glebas K, Bliesath JT, Ligonzio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
60. Famularo,G, Mosca L, Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr Pharm Design 2003; 9(24): 1973-80.
61. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Design 2003; 9(14): 1107-13.
62. Patton AM, Kassis J, Doong H, Kohn EC. Calcium as a molecular target in angiogenesis. Curr Pharm Design 2003; 9(7): 543-51.